JP2023530166A5 - - Google Patents

Info

Publication number
JP2023530166A5
JP2023530166A5 JP2022577618A JP2022577618A JP2023530166A5 JP 2023530166 A5 JP2023530166 A5 JP 2023530166A5 JP 2022577618 A JP2022577618 A JP 2022577618A JP 2022577618 A JP2022577618 A JP 2022577618A JP 2023530166 A5 JP2023530166 A5 JP 2023530166A5
Authority
JP
Japan
Prior art keywords
approximately
composition according
topical composition
fluticasone
corticosteroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022577618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530166A (ja
JP7791119B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/055222 external-priority patent/WO2021255622A1/en
Publication of JP2023530166A publication Critical patent/JP2023530166A/ja
Publication of JP2023530166A5 publication Critical patent/JP2023530166A5/ja
Application granted granted Critical
Publication of JP7791119B2 publication Critical patent/JP7791119B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022577618A 2020-06-15 2021-06-14 アルカフタジンとコルチコステロイドの組み合わせ Active JP7791119B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921053286 2020-06-15
IN201921053286 2020-06-15
PCT/IB2021/055222 WO2021255622A1 (en) 2020-06-15 2021-06-14 Combination of alcaftadine and a corticosteroid

Publications (3)

Publication Number Publication Date
JP2023530166A JP2023530166A (ja) 2023-07-13
JP2023530166A5 true JP2023530166A5 (https=) 2024-06-06
JP7791119B2 JP7791119B2 (ja) 2025-12-23

Family

ID=76523259

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022577618A Active JP7791119B2 (ja) 2020-06-15 2021-06-14 アルカフタジンとコルチコステロイドの組み合わせ

Country Status (12)

Country Link
US (1) US20230218630A1 (https=)
EP (1) EP4164614A1 (https=)
JP (1) JP7791119B2 (https=)
KR (1) KR20230024928A (https=)
CN (1) CN115701988A (https=)
AU (1) AU2021291684A1 (https=)
BR (1) BR112022024840A2 (https=)
CA (1) CA3181959A1 (https=)
CL (1) CL2022003534A1 (https=)
MX (1) MX2022015965A (https=)
WO (1) WO2021255622A1 (https=)
ZA (1) ZA202212128B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
JP7606530B2 (ja) 2020-03-24 2024-12-25 シラノ セラピューティクス, インコーポレイテッド コロナウイルス感染症による化学感覚機能障害の治療
US20240173331A1 (en) 2021-04-01 2024-05-30 Alkem Laboratories Limited Nasal compositions comprising alcaftadine
CA3246013A1 (en) * 2022-01-06 2023-07-13 Cyrano Therapeutics, Inc. IMPROVED NASAL ADMINISTRATION OF PHARMACEUTICAL FORMULATIONS
WO2024228988A2 (en) * 2023-05-02 2024-11-07 Cyrano Therapeutics, Inc. Treatment for taste and smell loss
GR1010821B (el) * 2023-11-09 2024-11-15 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Σταθερο ομογενοποιημενο φαρμακευτικο ρινικο εναιωρημα συνδυασμου αζελαστινης και φλουτικαζονης

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3877904D1 (de) 1987-11-13 1993-03-11 Asta Pharma Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge.
IL101850A (en) 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv 11-(4-Piperidinyl)-imidazo (2,1-b) (3) benzazepine derivatives their preparation and pharmaceutical compositions containing them
DE19947234A1 (de) * 1999-09-30 2001-04-05 Asta Medica Ag Neue Kombination von Loteprednol und Antihistaminika
KR20050044550A (ko) * 2001-12-05 2005-05-12 알콘, 인코퍼레이티드 비염 치료를 위한 η1 길항제 및 안전한 스테로이드제의용도
PL1919450T3 (pl) 2005-09-01 2014-11-28 Meda Ab Kompozycja liposomowa zawierająca lek przeciwhistaminowy i kortykosteroid oraz jej zastosowanie do wytwarzania leku do leczenia nieżytu nosa i chorób spokrewnionych
BRPI0710085B8 (pt) * 2006-03-31 2021-05-25 Vistakon Pharmaceutical Llc composições oftálmicas e seus kits
US8569273B2 (en) * 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
WO2011141929A2 (en) * 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
CN102283849A (zh) * 2011-06-29 2011-12-21 北京阜康仁生物制药科技有限公司 一种含有阿卡他定的药物组合物
RU2652352C2 (ru) * 2012-12-17 2018-04-25 Глаксо Груп Лимитед Комбинация левокабастина и флутиказона фуроата для лечения воспалительных и/или аллергических состояний
MX367674B (es) * 2013-09-13 2019-08-30 Glenmark Specialty Sa Composición farmacéutica de dosis fija estable que comprende mometasona y olopatadina.
WO2019022225A1 (ja) 2017-07-28 2019-01-31 参天製薬株式会社 アルカフタジン又はその塩を含有する水性医薬組成物

Similar Documents

Publication Publication Date Title
JP2023530166A5 (https=)
Herman Once-daily administration of intranasal corticosteroids for allergic rhinitis: a comparative review of efficacy, safety, patient preference, and cost
HRP20200495T1 (hr) Sastavi za liječenje gastrointestinalne upale
RU2011135824A (ru) Применение глюкокортикоидной композиции для лечения тяжелой и неконтролируемой астмы
HRP20140864T1 (hr) Kombinacije koje sadrže antimuskarinska sredstva i beta-adrenergiäśke agoniste
IL216932A (en) Composition of pharmaceuticals containing azalastine and cyclozonide and method for the manufacture of a periodic allergy treatment containing this composition
JP2010540671A5 (https=)
JP2011528355A (ja) 充血除去剤およびコルチコステロイドを含む鼻腔内粗製物
JP2015506983A5 (https=)
HRP20100104T1 (hr) Kombinacije koje sadrže antimuskarinska sredstva i kortikosteroide
WO2011141929A2 (en) Aqueous pharmaceutical compositions of fluticasone and olopatadine
US20090022671A1 (en) Treatment methods
JP2001508034A (ja) 鼻ポリープの治療におけるh▲上+▼,k▲上+▼―atpアーゼ阻害剤の使用
JP2006518382A5 (https=)
Meltzer et al. New intranasal formulations for the treatment of allergic rhinitis.
Rohatagi et al. Absolute oral versus inhaled bioavailability: significance for inhaled drugs with special reference to inhaled glucocorticoids
US20070249572A1 (en) Systems and methods for the delivery of corticosteroids
WO2007075963A2 (en) Systems and methods for the delivery of corticosteroids
JP2014515360A (ja) フルチカゾンを含む鼻用医薬製剤
US20070178050A1 (en) Methods and systems for the delivery of corticosteroids having an increased lung depositon
US20070197486A1 (en) Methods and systems for the delivery of corticosteroids
JP2011503109A5 (https=)
US20070160542A1 (en) Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
NZ590427A (en) Pharmaceutical compositions based on kinin b2 receptor antagonists and corticosteroids, and their use
US20070178049A1 (en) Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile